1q 1136
131I 632
[18F]FDG 481
[18F]FLT 481,
2-deoxy-d-glucose 1842
2-methoxyoestradiol 1433
2-methoxyoestradiol-3,17-O,O-bis-sulphamate 1842
4T1 model 741
5-fluorouracil 716, 1020
7p 774
8q 774
α-fetoprotein 72
ABC transporter 1651
access to health care 1040
accrual rates 1967
ACSL3 314
ACSL3: ETV1 fusion 314
active immunotherapy 350
adenovirus 1668
adherence 428, 1763
adiponectin 1246
adjuvant chemotherapy 597, 1226, 1232
adjuvant treatment 875
adolescent HPV vaccination 1908
adrenocortical carcinomas 1900
adult gliomas 1153
advanced breast cancer 1984
advanced cancer 1251
advanced gastric cancer 858
advanced solid tumours 1387
aetiology 545
AFP 72
age 1007, 1046
age at menarche 201
age inequalities in cancer care 1967
AIDS 800
AKT 1265, 1296
AKT1 488
albumin 1013
alcohol 805
allele-specific PCR 90
anaemia 14
anaplastic 781
androgen receptor 1743
angiogenesis 160, 321, 622, 1348, 1375, 1387, 1433, 1557, 1961, 2054
angiotensin receptors 160
antagonists and inhibitors 616
anthropometric factors 207
anthropometry 201
antiangiogenic 1197
anti-angiogenesis 734, 1204
antibody-drug conjugate 100
anti-cancer drug 1442, 2044
anti-CEA antibody targeting 632
anti-EGFR therapy 868
antiretroviral drugs 800
anxiety 1794
AP-1 1269, 2013
APC 1735
Apo-2L 294
apoptosis 283, 294, 841, 989, 1442, 1816, 1823
ARE1 -158 G/A polymorphism (rs266882) 1743
aromatase inhibitor 428
AS1404 2006
ASA404 2006
asbestos 173, 822
asbestos removal 822
astrocytomas 160, 294
atypical squamous cells of undetermined significance (ASCUS) 563
automated fluorescence microscope 789
awareness 1593
azathioprine 1276
β2-microglobulin 1453
basal cell carcinoma 1276
Bayesian analysis 1786
BCL-2 family proteins 1613
behavioural intention 225
bevacizumab 93, 1564
biliary tract cancer 811
biliary tract carcinoma 862
bioluminescent imaging 2037
biomarkers 655, 841, 1103
birth weight 1161, 1544, 1916
bis-sulphamates 1433
biweekly schedule 455
BK virus 1383
bladder cancer 1383
BLT2 1064
BMI 1517, 1912
BNIP3 727
body mass index 185, 527, 811, 1916
body size 196, 1517
BRAF 83, 2020, 2065
BRAF gene 1673
brain tumour 796
brain tumour stem cells 2044
BRCA1 371, 974
BRCA1/2 1302, 1534
BRCA2 371, 974
breast 327, 1842
breast cancer 68, 196, 335, 387, 404, 408, 415, 423, 428, 513, 539, 597, 604, 704, 711, 774, 930, 974, 1000, 1089, 1170, 1185, 1221, 1226, 1357, 1369, 1433, 1502, 1534, 1544, 1623, 1644, 1763, 1775, 1940
breast cancer cell line 1246
breast cancer cells 481
breast cancer metastases 741
breast cancer risk 201, 207
breast cancer screening 1176
breast carcinoma 63, 611, 639
breast neoplasms 616
breast volume 1534
cachexia 2029
calcium 1539
cancer awareness 1221
cancer incidence 191
cancer registries 1923
cancer screening 655
cancer stem cells 387
cancer stromal cell 305
cancer survival 830, 1923
cancer susceptibility 670
cancer-associated fibroblasts 1375
capecitabine 584, 591, 858, 1316
carbonic anhydrase 9 1468
carboplatin 51, 894
carcinogenesis 1961, 2070
carcinoma 245, 1493
cardia 1506
case–control study 423
caspases 283
caveolin 1 327, 1684
caveolin 2 327
c-Cbl 1849
CCI-779 1197
CD133 100, 1285
CDKN2A 364
cDNA microarray 335
C/EBPβ 781
cell cycle 1635, 1823
cell invasion 1114
cell lines 1330
cell signalling 750
central obesity 527
Cervarix 1908
cervical cancer 225, 1096, 1216, 1557, 1651, 1929
cervical intraepithelial neoplasia 239
cervical intraepithelial neoplasia (CIN) 563
cetuximab 83, 455
c-Fos 1269
CFUgm 632
CGH 1136
ChA 72
chemoendocrine therapy 1564
chemokines 930, 1493
chemo-radiation 57
chemoradiotherapy 1020
chemosensitising 1832
chemosensitivity testing 760
chemotherapy 6, 23, 44, 51, 57, 63, 266, 283, 442, 481, 591, 695, 868, 900, 1000, 1395
chemotherapy response 387
chest X-ray 557
childhood 796, 1129, 1529, 1539, 1916
childhood cancer 179
childhood leukaemia 219, 1668
childhood nutrition 1517
China 196, 811
CHK2 or CHEK2 (checkpoint kinase 2) 1302
choroid 1673
chromosome damage 670
chronic myelogenous leukaemia 387
CI-1040 2020
ciliary body 1673
circulating tumour cells 789, 841
cisplatin 167, 442, 852
c-KIT 2065
claudin-4 491
clear cell carcinoma 1197
clinical trials 1593, 1967
coffee 1534
cohort study 191, 1165, 1946
collagen IV 68
colon cancer 966, 2094
colorectal 275, 1285
colorectal cancer 133, 136, 266, 459, 532, 632, 716, 727, 1046, 1050, 1239, 1316, 1511, 1607, 1718, 1729, 1867, 1923, 1991, 2088
colorectal, prostate and ovarian cancer 789
combination 1
combination therapy 689
combined modality therapy 900
combretastatin 321
common gene activation 1307
community 1763
compliance 428, 1593
concurrent chemoradiation 167
contralateral cancer 539
corticosteroids 23
cost-effectiveness 230, 557, 1984
Cox regression 179
CpG island 136
cribriform patterns in thyroid tumour 1874
c-Src activation 1769
CT screening 557
curative surgery 1046
cure 219
CXCL13 930
CXCR4 1623, 1695
cyclooxygenase-2 1729
CYP1B1 1056
CYP2C19 1251
CYP3A4 1239
CYPIA2 1534
Cyr61 1656
cystine transporter 464
cytochrome P-450 2D6 616
cytogenetic 1673
cytokeratins 841
cytotoxic agents 1
dasatinib 1074
deep vein thrombosis 1034
definitive chemoradiotherapy 1586
depression 1794
depressive mood 1408
deprivation 1923
dermcidin 126
dexamethasone 2054
diabetes 1380
diagnostic marker 939
dietary folate 816
dietary patterns 191, 1511
differential expression 1136
differentiation 1849
disease progression 1572
disease-free survival 966
disease-specific survival 539, 1476
distant metastases 513
distress 1975
diuretics 1522
DKK3 663
DLEC1 375
Dll4 1204
DMXAA 2006
DNA methylation 136
DNA microarray 1484, 1635
DNA-repair genes 1050
docetaxel 852, 1426, 1832, 2054
dose 275, 722
dose fractionation 632
dose intensity 253, 1226
dose reduction 259
doxorubicin 442, 1816
drug metabolism 1251
drug resistance 118, 387, 464, 473, 1808
drug targeting 392, 900, 1256
Du145 1656
dynamic MRI 321
early life 796, 1544
eastern Europe 1912
E-cadherin 1832
economic evaluation 1232
economics 1991
ECX 868
efficacy 584
efficiency 2001
EGCG 647, 1056
EGFR 83, 245, 341, 911, 923, 1056
EGFR inhibitors 473
EGFR-targeting drugs 1
EGFRvIII 341
elderly patients 51, 584, 1586
elective 1046
EndMT 1375
endocrine-responsive breast cancer 1564
endometrial adenocarcinoma 1034
endometrial cancer 434, 1651
endometrial stromal sarcoma 1210
endosialin 1348
endothelial 1204
endothelial-to-mesenchymal transition 1375
Endothelin-converting enzyme-1 (ECE-1) 1114
endothelium 1256, 1375
engineered antibody 1415
enzastaurin 750
ependymoma 1129, 1136
EphA2 1074
EPIC Study 191
epidemiology 1522, 1529, 1946
epidermal growth factor receptor 90, 1729, 1757
epigenetics 136
epirubicin 858
epithelial 1476
epithelial cell adhesion molecule (EpCAM) 1635
epithelial–mesenchymal interactions 151
epoetin-β 14
Epstein–Barr virus 1816
ErbB 1415
ERCC1 167
ERG 847
ERK1/2 2020
erlotinib 93, 911
ER-positive breast cancer 1769
ethnicity 1040, 1757
ETS 847
Ets-1 1348
ETV1 314
EXE 858
exercise 30
expert rating scale 37
exploratory trial 415
faecal tumour M2 pyruvate kinase 133
false-positive cases 239
familial predisposition 1748
familial risk 536
family history of breast cancer 1007
Fas ligand 502, 1600
Faslodex 1984
fatigue 23, 30, 1408
FBLN1 2083
female neoplasms 816
fibroblast growth factor receptor 2, 10, 305
fibrosis 1375
focus genes 1307
FOLFOX 1395
follow-up 704
Frizzled 143
FTIR microspectroscopy 1859
fuel 1934
fulvestrant 1984
fusion 847
G3 endometrioid endometrial carcinoma 768
GA733 1290
gallstones 811
gastric 100
gastric adenocarcinoma 949
gastric cancer 126, 584, 1307, 1322, 1802, 2083
gastrointestinal stromal tumour 448, 1600
gemcitabine 760, 862, 1387
GEMOX 862
gender 1506
gene expression 1330
gene expression profiling 1307, 1729, 1884
gene regulation 978, 1246
gene signature 1884
genetic susceptibility 536, 1748
genome profiling 387
genomic instability 1121
genotyping 563
germ cell tumour 1748
γH2AX 1129
Gleason grade 1859
glioblastoma 294, 1678, 2044
glioma 185, 294, 1144
glomerular filtration rate 894
glucose level 1380
glutathione 464
glycaemic index 434, 1170
glycaemic load 434, 1170
glycolysis 989
GOLPH2 939
GP73 939
granulocyte colony-stimulating factor 253
Great Britain 822
Greece 191
green tea 1179
green tea polyphenol 647
group rehabilitation 1975
GSTP1 1316
GTG banding (G-bands after trypsin and giemsa) 1302
Guthrie card 1668
H19 1891
hCGβ 72
HDAC inhibitors 1623
head and neck cancer 57, 93, 167
health-related quality of life 1975
height 185, 1916
hepatitis C 805
hepatoblastoma 1891
hepatocarcinogenesis 151
hepatocellular 100
hepatocellular carcinoma 143, 805
hepatocyte growth factor 1623
HER family 1775
HER-2 68, 520
HER-2/neu 341
hereditary non-polyposis colorectal cancer 1726
heritable tumour syndromes 683
heterogeneity 1673
HIF-1α 459, 1442
HIF-2 1348
high-risk HPV 404
highly sensitive in situ hybridisation 350
histone deacetylase 689
HIV 800
Hiwi 1083
HL60 670
HLA class I antigen 1462
HNF3β/FoxA2 781
HNSCC 357
home 1934
hormonal therapy 611
hormone receptor 196
hormone receptor positive 1984
hormone refractory 1296
hormones 1161
HPV 214, 230
HPV-16 408
HPV prevalence 1929
human chorionic gonadotrophin subunit β 72
human papilloma virus (HPV) 225, 408, 563
human tissue kallikreins 1103
hypermethylation 357
hypertension 1912
hypothyroidism 448
hypoxia 727, 1348, 1442, 1468
hysterectomy 1216
Id-1 1557, 1832
Id-1 gene 404
IGF binding protein 3 1096
IGF1R 83
IGF2 1891
IGFs 1357
imatinib 734, 1600
immune evasion 1867
immune function 2029
immunohistochemistry 321, 327, 335, 639, 939, 957, 1285, 1453, 1704, 1712
immunosuppression 1276
implementation 415
in utero 545
incidence 176, 182, 1502, 1940
Indonesia 214
induction 57
infection 1529
inflammation 1251, 2029, 2070
inflammatory breast cancer 1735
inflammatory cells 1013
information 1908
informed 1007
infrared spectroscopy 1859
inhibitor 689, 911
inositol hexakisphosphate 1613
insulin-like growth factor-1 receptor 1096
integrative approach 1307
integrin β1 1684
intercostobrachial neuropathy 604
intra-uterine growth 179
intraperitoneal therapy 2037
invasion 663, 1322, 1453
involution 1369
ionising radiation 1940
IPMN 1064
ipsilateral breast relapse 539
IR (ionising radiation) 1302
irinotecan 275, 455, 577, 1239, 1316, 1607
irradiation 93
isothiocyanates 1823
Italy 173, 225
Jak-Stat pathway 2044
Japan 176, 1502, 1179
Kaposi sarcoma 800
Kdr 1204
Ki-67 1013, 1121
Ki-67/MIB-1 72
kidney cancer 1912
KIT 2065
KLHL9 364
KLK6 1484
KLK10 1484
knowledge 1007
KRAS 83, 245, 923, 2020
kRT-PCR 1775
lapatinib 711
laser microdissection 1735
laser-capture microdissection 1849
lentivirus 622
leukaemia 1529
leukotriene B4 1064
life expectancy 1991
liposomes 392, 1256
liquid-based cytology (LBC) 563
Listeria monocytogenes 741
LIV-1 774
liver metastasis 350, 716, 957, 1729
LKB1 245, 683
localised 1027
locoregional recurrence 1121
long-term effects 30
longitudinal study 1794
loss of heterozygosity 1891
loss of imprinting 1891
low-dose rate exposure 1940
low-grade squamous intraepithelial lesion (LSIL) 563
LPA 1322
lung cancer 173, 557, 683, 852, 911, 1179, 1635, 1757, 1934
LXXLL motif 639
LY294002 2013
lymphangiogenesis 110
lymphoid leukaemia 488
lymphoma 1387
MAGE-A protein 350
MAGE-A10 mRNA 350
Mage-b DNA vaccine 741
MAL 1802
malignancy 545
malignant neoplasms 1549
malignant pleural mesothelioma 44, 51
mammary epithelial cell 1246
mammographic density 1369, 1539
mammography 1007, 1176
mammography screening 1185
MAPK 1089, 1823
margins 357
marker expression 491
mass screening 239
maternal age 1161
MDA-MB-231 1056
MDM2 1144
Mdm2 SNP309 78
Mediterranean diet 191
MegaFasL 1600
melanoma 536, 1265, 1673, 1678, 2065
melanoma-prone families 364
meningioma 182, 185
menopausal status 196
MET 83, 911
meta-analysis 434, 1170, 1340
metabolism 989
metastasis 110, 398, 923, 957, 1718
metastatic breast cancer 1572
metastatic colorectal cancer 455, 577, 722
metastatic gastric cancer 1402
metastatic melanoma 734
methionine 816
methylation 1735, 2083
methylation-specific PCR 1735
microarrays 398, 768, 1330, 1729, 1884
microenvironment 1484
microsatellite instability 1607, 1726, 1867
microtubule 1842
microvessel density 321, 1013, 1961
middle aged 239
midkine 655
MI-ER1 639
migration 1322, 1453, 1493
mismatch repair 375
mitochondria 989, 2088
mitomycin C 591
MnSOD 283
modelling 1991
molecular diagnosis 1859
molecular markers 2001
mortality 173, 253, 822, 1549, 1763, 1934
motesanib diphosphate 1387
motility 520
MRE11 1607
mRNA 1775
MSC 622
MT1-MMP 663
mTOR 1056
mTORC2 1197
MUC1 978
MUC4 520, 949
mucin 949
mucosal 2065
multiparametric analysis 1103
multiple primary neoplasm 1340
multiplex ELISA 841
multiplex ligation-dependent probe amplification 364
muscle strength 30
mutation screening 90
mutations 245, 488, 923, 1265, 2020
MYCN gene 1027
nanomedicines 392, 900
National audit 695
national cancer statistics 830
natural killer-cell malignancies 1816
NB7M 1823
NEAT 1226
neoadjuvant 1020
neoplasm 1408, 1506
neprilysin 1114
NET1 1322
network mapping 1307
neuroblastoma 1027, 1165
neuroendocrine markers 1330
neuroendocrine tumours 72, 1330
neuropathic pain 604
neuropilin 1153
Nfkb1 2070
niacin 816
NLS (nuclear localisation signal) 1302
non-clear cell histology 259
non-Hodgkin's lymphoma 253
non-seminoma 1517
non-small cell lung cancer 245, 750, 852, 2006, 2013
normal mucosa 136
Norway 1165
Notch1 1204
Nrf2 2070
NSCLC 375, 923, 1476
nuclear 1769
nuclear factor-κ B 1816
nuclear localisation 639
nucleoside transporter 760
nucleosomal DNA 841
nutrition 2029
obesity 527, 811, 995
occupational exposure 822
oesophageal cancer 126, 1020, 1395, 1586
oesophageal squamous cell carcinoma 1462, 1468
oesophagogastric cancer 868
oesophagus 1506
oestrogen receptor 639, 774
older women 1221
oral cancer 1121
oral cancer invasion 647
oral contraceptive 1534
oral squamous cell carcinoma 655, 1453
organ transplant recipients 1276
orthotopic 93, 110
outcome 727
ovarian cancer 283, 341, 434, 520, 1103, 1269, 1794, 1823, 1916, 2020, 2037
overdiagnosis 1176
oxaliplatin 577, 858, 862, 1020, 1050, 1395
p14ARF 364, 1144
p16INK4a 110, 364
P38 1808
p53 118, 974
p53 pathway 78
paclitaxel 1678, 2037
paediatric oncology patient 23
paediatrics 894
pancreas 622
pancreatic cancer 6, 110, 126, 305, 464, 527, 760, 1064, 1074, 1083, 1290, 1484
pancreatic cancer progression 1695
PanIN 1064
papillary 781
papillary thyroid carcinoma 1874
par6 1476
parents 1908
parity 1161
patient values 875
patient–doctor agreement 415
PCa 1656
PC-DFA 1859
pemetrexed 51, 750
perception 1593
perinatal 1165, 1544
PET 481
Peutz-Jeghers syndrome 683
pharmacodynamics 1579
pharmacogenetics 716, 1050, 1251
pharmacogenomic 1757
pharmacokinetics 1239, 1387, 1433, 1579
pharmacology and therapeutic use 616
pharmacovigilance 253
phase I 1579
phase II 734
phosphatase 1718
phosphatidylinositol 3-kinase pathway 2013
photosensitising reaction 1522
physical activity 1408
physical status 408
Physicians’ Health Study 1743
PKCα 1808
PKCδ 1808
plasma D-dimer 1034
platelet-derived growth factor receptor 1426
pleural cancer 173
ploidy 513, 1121
PMPS 604
polymer therapeutics 900
polymers 392
polymorphisms 716, 978, 1050, 1357
population based 214, 1506
positivity criterion 415
positron emission tomography 989
postnatal growth 1544
postoperative pain 604
potassium channels 989
PPARγ 2044
PRAME 398
prediction of therapy 1103
predictions 1549
predictive value 1775
pre-malignant 1961
prenatal infection 1668
preoperative therapy 852, 1564
prevalence 214
prevention 532, 995
primary breast cancer 1013
primary chemotherapy 68
primary culture 1678
primary tumour 923
principal components analysis 1511
PRL-3 1718
PRMT1 2094
procoagulants 1000
prognosis 160, 335, 341, 357, 375, 398, 539, 655, 1083, 1089, 1129, 1285, 1462, 1468, 1651, 1712, 2094
prognostic factors 1027, 1210, 1269, 1402
prognostic indicator 1557
prognostic marker 1802, 1884
prognostic value 1775
progression 1269
proliferation 335, 1635, 1635, 1884
proliferation signature 966
proliferative activity 513
prominin-1 100
promoter hypermethylation 1802
promoter methylation 375
promoters 1144
prophylactic HPV vaccine ‘CervarixÔ’ 1929
prospective cohort studies 176, 1179, 1502, 1511
prospective study 448
prostaglandin E2 502
prostate 1296, 1842
prostate cancer 78, 126, 176, 314, 371, 491, 847, 939, 1040, 1114, 1426, 1613, 1743, 1786, 1832, 1849, 1859, 2054
proteasome inhibitors 1613
protein arginine methyltransferase 2094
protein kinase Cβ 750
protein kinase Cδ 1644
protein tyrosine kinases 734
PSA gene 1743
pseudomyxoma peritonei 591
psycho-oncology 37
psychosocial distress 37
psychosocial support 1975
PTCH gene 1276
PTEN 341, 1089, 1296
PTK6 (BRK) 1089
pulmonary 597
pulmonary thromboembolism 1034
QMSP 357
Q-TWiST 711
quality of life 30, 415, 1226
quality-adjusted survival 711
Rac1 1656
RAD50 1607
radiation 545, 1216, 1946
radiation sensitivity 670
radioimmunotherapy 632
radiology 1185
radiosensitisation 1442
radiotherapy 63, 266, 900, 1395
radon 1946
randomised clinical trial 442
rapamycin 1197
receiver operating characteristic curve 1712
receptor tyrosine kinase 1074
RECK hypermethylation 647
record-linkage study 805
rectal cancer 1232, 1712, 1923
recurrence 357
registries 182
regulation 502
regulatory T cells 1867
rehabilitation 30
relative survival 1786
renal cell cancer 259, 448, 1380
renal function 894
resection 266
residual disease 1216
resistance 911
response 275, 1020
RET/PTC3 and E7 transgenic mice 1874
review 683
RFLP 78
RhoA 1322
riboflavin 816
risk 1369, 1522, 2088
risk factors 179, 545
risk modelling 557
RNA and protein 491
RNAi 1695
S-1 584
S100 proteins 1136
safety 584
SAGE 1136
salivary adenoid cystic carcinoma 90
salivary glands 90
Sam68 1089
sandwich ELISA 768
schedule dependency 1808
schools 1908
screening 133, 532, 557
second cancers 253, 536, 611
second-line chemotherapy 1402
securin 335
semaphorin 1153
seminoma 1517
serine proteases 1103
serotonin reuptake inhibitors 616
serum collagen IV 68
serum markers 768, 930
service screening 423
sex steroids 201
shared decision-making 875
signalling pathways 1623
signet ring cell carcinoma 949
Singapore Chinese 1511
single and multiple HR cases 1929
single nucleotide polymorphism 1340
size at birth 201
skin cancer 1522
sleep duration 176, 1502
sleeping problems 1408
Smad7 957
small-cell lung cancer 442
smoking 1161, 1912
smooth-muscle myosin 1726
Snail 1900
SNP309 1144
socioeconomic deprivation 830
soy 196
spatial models 1786
splicing 978
squalene epoxidase 774
squamous cell carcinoma 167
squamous cell carcinoma of the head and neck 1684
Src 1684
stage IB/II 852
stage-III 1718
STK11 683
stomach cancer 350, 1704
stool testing 133
stopping rule 2001
stove 1934
stromal 1476
SULT1A1 1340
sunitinib 259, 448, 1380
suppressor 1114
surgery 63
survival 14, 63, 219, 266, 398, 1013, 1046, 1210, 1269, 1285, 1316, 1357, 1426, 1572, 1900, 2001
survival analysis 1704
sustained chemotherapy 2037
Swiss HIV cohort study 800
systemic therapy 695
TAM67 2013
tamoxifen 428, 616, 1056, 1763, 1769
targeted therapy 473, 1290
TEAD1 1849
Techa River 1940
teenagers and young adults 830, 1967
tegafur–uracil 577
telatinib 1579
telephone follow-up 704
telomerase 1129
testicular cancer 1517, 1748
testicular microlithiasis 1748
TGF-β1 957, 1357
thiamin 816
thymidine kinase 481
thymidylate synthase 716
thyroid cancer 781
tissue array analysis 1704
tissue microdissection 1083
TMPRSS2 847
tobacco related cancer 1340
tocotrienol 1832
topoisomerase IIá 670
toxicity 259, 275, 597, 1316
TP53 727, 1144
Tpot 1678
transcript 978
transcription 663
translocation 847
transplant recipients 1383
treatment guidelines 875
treatment preferences 875
trefoil factor 768
trends 219, 830, 1549
trichostatin A 1623
TROP2 1290
tumour advancement 1557
tumour antigen 398
tumour expression 930
tumour growth 1493
tumour hypoxia 459
tumour immune evasion 502
tumour immunity 1867
tumour marker 72, 1712
tumour microenvironment 118
tumour proliferation 2037
tumour stroma 118, 151
tumour suppressor gene 2083
tumour-infiltrating lymphocyte 1704
tumour-VDA 2006
tyrosine kinase inhibitor 1380, 1579
UFT 577, 722
UGT1A1*28 275
UGT1A1 gene polymorphism 1239
ultrasound 1748
U-miners 1946
upper aerodigestive tract cancer 1340
uracil–tegafur 1232
urban–rural 207
urothelial cell carcinoma 663
uterine cancer 611
vaccination 230
vaginal smears 239
vascular disrupting agents 1256
vascular endothelial growth factor receptor 1579
vascular maturity 321
VDA 2006
VEGF 622, 1153, 1380
venous thromboembolism 1000
vimentin 1476
vinorelbine 44
viral aetiology 1668
viral load 408
vitamin D 1539
waist-to-hip ratio 527, 811
waiting times 695
weight gain 995
weight loss 995
WNT 143, 1695
women 185
xCT 464
xenografts 1074
X-irradiation 1442
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Keyword Index for Volume 99. Br J Cancer 99, 2110–2113 (2008). https://doi.org/10.1038/sj.bjc.6604832
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6604832